CN106177931B - 免疫检测点双阻断ctl高效率杀伤细胞制剂的制备方法 - Google Patents
免疫检测点双阻断ctl高效率杀伤细胞制剂的制备方法 Download PDFInfo
- Publication number
- CN106177931B CN106177931B CN201610716772.4A CN201610716772A CN106177931B CN 106177931 B CN106177931 B CN 106177931B CN 201610716772 A CN201610716772 A CN 201610716772A CN 106177931 B CN106177931 B CN 106177931B
- Authority
- CN
- China
- Prior art keywords
- cell
- ctl
- preparation
- detection point
- double
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 39
- 230000000903 blocking effect Effects 0.000 title claims abstract description 24
- 238000001514 detection method Methods 0.000 title claims abstract description 18
- 230000002147 killing effect Effects 0.000 title claims abstract description 18
- 210000004027 cell Anatomy 0.000 claims abstract description 73
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 52
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 46
- 239000012636 effector Substances 0.000 claims abstract description 24
- 229940029030 dendritic cell vaccine Drugs 0.000 claims abstract description 21
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims abstract description 18
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims abstract description 18
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 17
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims abstract description 16
- 102000036639 antigens Human genes 0.000 claims abstract description 15
- 108091007433 antigens Proteins 0.000 claims abstract description 15
- 230000003321 amplification Effects 0.000 claims abstract description 12
- 239000000427 antigen Substances 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 11
- 238000004113 cell culture Methods 0.000 claims abstract description 10
- 239000000725 suspension Substances 0.000 claims abstract description 9
- 238000000926 separation method Methods 0.000 claims abstract description 7
- 230000001464 adherent effect Effects 0.000 claims abstract description 5
- 210000005259 peripheral blood Anatomy 0.000 claims abstract description 4
- 239000011886 peripheral blood Substances 0.000 claims abstract description 4
- 108010002350 Interleukin-2 Proteins 0.000 claims description 29
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 18
- 230000014509 gene expression Effects 0.000 claims description 17
- 238000003306 harvesting Methods 0.000 claims description 17
- 239000013589 supplement Substances 0.000 claims description 17
- 238000005119 centrifugation Methods 0.000 claims description 9
- 230000006044 T cell activation Effects 0.000 claims description 6
- 210000004881 tumor cell Anatomy 0.000 claims description 6
- 230000001413 cellular effect Effects 0.000 claims description 5
- 239000002504 physiological saline solution Substances 0.000 claims description 5
- 229920006395 saturated elastomer Polymers 0.000 claims description 5
- 210000003995 blood forming stem cell Anatomy 0.000 claims description 4
- 239000001963 growth medium Substances 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 3
- 108090000978 Interleukin-4 Proteins 0.000 claims description 3
- 239000012503 blood component Substances 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 238000001802 infusion Methods 0.000 claims description 3
- 210000004698 lymphocyte Anatomy 0.000 claims description 3
- 239000002609 medium Substances 0.000 claims description 3
- 238000012549 training Methods 0.000 claims description 3
- 229960005486 vaccine Drugs 0.000 claims description 3
- 210000000601 blood cell Anatomy 0.000 claims description 2
- 238000011534 incubation Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000012679 serum free medium Substances 0.000 claims description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 9
- 238000005516 engineering process Methods 0.000 abstract description 7
- 230000003013 cytotoxicity Effects 0.000 abstract description 3
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 3
- 230000005764 inhibitory process Effects 0.000 abstract description 3
- 230000033228 biological regulation Effects 0.000 abstract description 2
- 210000002966 serum Anatomy 0.000 abstract description 2
- 230000009977 dual effect Effects 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 description 9
- 208000026310 Breast neoplasm Diseases 0.000 description 9
- 238000001994 activation Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 102000008096 B7-H1 Antigen Human genes 0.000 description 7
- 108010074708 B7-H1 Antigen Proteins 0.000 description 7
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 7
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 238000003556 assay Methods 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 5
- 210000004907 gland Anatomy 0.000 description 5
- 230000003248 secreting effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108010045634 B7 Antigens Proteins 0.000 description 2
- 102000005738 B7 Antigens Human genes 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 238000011579 SCID mouse model Methods 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 201000010897 colon adenocarcinoma Diseases 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 206010001167 Adenocarcinoma of colon Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2304—Interleukin-4 (IL-4)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610716772.4A CN106177931B (zh) | 2016-08-25 | 2016-08-25 | 免疫检测点双阻断ctl高效率杀伤细胞制剂的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610716772.4A CN106177931B (zh) | 2016-08-25 | 2016-08-25 | 免疫检测点双阻断ctl高效率杀伤细胞制剂的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106177931A CN106177931A (zh) | 2016-12-07 |
CN106177931B true CN106177931B (zh) | 2018-02-02 |
Family
ID=57524443
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610716772.4A Active CN106177931B (zh) | 2016-08-25 | 2016-08-25 | 免疫检测点双阻断ctl高效率杀伤细胞制剂的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106177931B (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105163745B (zh) | 2013-03-01 | 2020-06-12 | 美国卫生和人力服务部 | 从外周血中产生肿瘤反应性t细胞富集群的方法 |
CN108379569B (zh) * | 2018-05-11 | 2022-12-02 | 北京百益宁医学科技有限责任公司 | 高效荷载肿瘤抗原的dc疫苗及其诱导扩增肿瘤抗原特异性ctl的方法 |
EP3721899A1 (en) * | 2019-04-08 | 2020-10-14 | China Medical University | Combination therapies comprising dendritic cells-based vaccine and immune checkpoint inhibitor |
CN110511906A (zh) * | 2019-05-16 | 2019-11-29 | 安徽瑞达健康产业有限公司 | 一种细胞组合物在癌细胞smmc-7721上的应用 |
CN111285931B (zh) * | 2020-02-05 | 2022-09-27 | 天津医科大学肿瘤医院 | 一种e-asv多肽及其在制备非小细胞肺癌新抗原疫苗中的用途 |
CN113046313A (zh) * | 2021-03-18 | 2021-06-29 | 重庆福美干细胞生物科技发展有限公司 | 用于高效诱导扩增人体外周血杀伤性免疫细胞的组合物、试剂盒以及该免疫细胞的培养方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1990044A (zh) * | 2005-12-30 | 2007-07-04 | 上海中科英达生物技术有限公司 | 人体免疫活性细胞dccik抗肿瘤细胞制剂的制备方法及应用 |
CN102526716A (zh) * | 2011-12-07 | 2012-07-04 | 蔡颖 | 一种特异性肿瘤杀伤细胞的制备 |
CN105695403A (zh) * | 2015-12-31 | 2016-06-22 | 深圳市中美康士生物科技有限公司 | 一种杀伤性免疫细胞的培养方法及其应用 |
CN105861433A (zh) * | 2016-04-27 | 2016-08-17 | 天津普瑞赛尔生物科技有限公司 | 制备具有高效肿瘤杀伤性cik细胞制剂的方法及制得的cik细胞制剂 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1198646C (zh) * | 1996-11-08 | 2005-04-27 | 生物基因Idec公司 | 抗体与人b7.1和b7.2之间独特结合相互作用的鉴定 |
-
2016
- 2016-08-25 CN CN201610716772.4A patent/CN106177931B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1990044A (zh) * | 2005-12-30 | 2007-07-04 | 上海中科英达生物技术有限公司 | 人体免疫活性细胞dccik抗肿瘤细胞制剂的制备方法及应用 |
CN102526716A (zh) * | 2011-12-07 | 2012-07-04 | 蔡颖 | 一种特异性肿瘤杀伤细胞的制备 |
CN105695403A (zh) * | 2015-12-31 | 2016-06-22 | 深圳市中美康士生物科技有限公司 | 一种杀伤性免疫细胞的培养方法及其应用 |
CN105861433A (zh) * | 2016-04-27 | 2016-08-17 | 天津普瑞赛尔生物科技有限公司 | 制备具有高效肿瘤杀伤性cik细胞制剂的方法及制得的cik细胞制剂 |
Also Published As
Publication number | Publication date |
---|---|
CN106177931A (zh) | 2016-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106177931B (zh) | 免疫检测点双阻断ctl高效率杀伤细胞制剂的制备方法 | |
Liau et al. | Treatment of a glioblastoma patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I–matched tumor peptides: case report | |
AU2006288348B2 (en) | Method for activation treatment of antigen-presenting cell | |
CN108379569B (zh) | 高效荷载肿瘤抗原的dc疫苗及其诱导扩增肿瘤抗原特异性ctl的方法 | |
AU2021200648A1 (en) | Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions | |
CN104946588A (zh) | 一种抗原特异性t淋巴细胞的分离和高效扩增培养方法 | |
CN104651311A (zh) | 制备dc-ctl的试剂盒及其应用 | |
JP2011529341A (ja) | ナチュラルキラー細胞の増殖方法 | |
Schuurhuis et al. | In situ expression of tumor antigens by messenger RNA–electroporated dendritic cells in lymph nodes of melanoma patients | |
JP2021533798A (ja) | エクソソームに基づく抗腫瘍ワクチン | |
JP6235085B2 (ja) | 高静水圧によって死滅させた腫瘍細胞および樹状細胞を用いた活性細胞癌免疫療法のための手段および方法 | |
JP5856025B2 (ja) | 単球またはnk細胞を入手する方法 | |
AU2010202385A1 (en) | Methods for inducing the differentiation of blood monocytes into functional dendritic cells | |
CA3084179A1 (en) | Prostate cancer specific marrow infiltrating lymphocytes and uses thereof | |
Mosca et al. | Dendritic cell vaccines | |
Dissanayake et al. | Peptide-pulsed dendritic cells have superior ability to induce immune-mediated tissue destruction compared to peptide with adjuvant | |
CN107541499B (zh) | 一种靶向免疫检测点tnfr2的cik的制备及其应用 | |
CN106047809A (zh) | 一种联合tlr7配体同时扩增人cik/nk细胞的方法 | |
CA2717038C (en) | Methods for inducing the differentiation of blood monocytes into functional dendritic cells | |
JP7397493B2 (ja) | 治療用途のための樹状細胞のin vitro分化および成熟のための方法 | |
CN105602900A (zh) | 一种经腺病毒基因修饰的肿瘤特异性细胞毒性t淋巴细胞的培养方法 | |
CN113728231A (zh) | 提供免疫细胞的方法 | |
CN113403275A (zh) | 一种特异性靶向癌种的新抗原制备方法 | |
US10716810B2 (en) | Canine autologous immunotherapy using dendritic cell induced cancer killing immunocytes | |
CN107496912B (zh) | 一种乙肝病毒抗原肽联合肝癌细胞抗原信息的抗原提呈信号群及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Cai Jianhui Inventor after: Zhang Wei Inventor after: Gao Fei Inventor after: Shi Long Inventor after: Cai Ying Inventor before: Cai Jianhui Inventor before: Zhang Wei Inventor before: Cui Hongjuan Inventor before: Li Dongbin Inventor before: Cai Ying |
|
COR | Change of bibliographic data | ||
CB02 | Change of applicant information |
Address after: The Yangtze River Road high tech Zone 050000 Hebei province Shijiazhuang Hongchang Science Park No. 238, No. 1 Building 2 layer Applicant after: HEBEI NONGFOYU BIOLOGY TECHNOLOGY Co.,Ltd. Address before: The Yangtze River Road high tech Zone 050000 Hebei province Shijiazhuang Hongchang Science Park No. 238, No. 1 Building 2 layer Applicant before: HEBEI LITONGKANG BIOTECHNOLOGY CO.,LTD. |
|
CB02 | Change of applicant information | ||
CB03 | Change of inventor or designer information |
Inventor after: Cai Shoufeng Inventor after: Zhang Wei Inventor after: Gao Fei Inventor after: Li Dongbin Inventor after: Cai Ziqi Inventor before: Cai Jianhui Inventor before: Zhang Wei Inventor before: Gao Fei Inventor before: Shi Long Inventor before: Cai Ying |
|
CB03 | Change of inventor or designer information | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20211209 Address after: 050000 1st floor, building 1, Hongchang Industrial Park, No. 238 Changjiang Avenue, high tech Zone, Shijiazhuang, Hebei Patentee after: Nongfuyu pharmaceutical Hebei Co.,Ltd. Address before: 050000 2F, building 1, Hongchang Science Park, No. 238 Changjiang Avenue, high tech Zone, Shijiazhuang City, Hebei Province Patentee before: HEBEI NONGFOYU BIOLOGY TECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CP01 | Change in the name or title of a patent holder |
Address after: 050000 1st floor, building 1, Hongchang Industrial Park, No. 238 Changjiang Avenue, high tech Zone, Shijiazhuang, Hebei Patentee after: Nongfuyu pharmaceutical Hebei Co.,Ltd. Address before: 050000 1st floor, building 1, Hongchang Industrial Park, No. 238 Changjiang Avenue, high tech Zone, Shijiazhuang, Hebei Patentee before: Nongfuyu pharmaceutical Hebei Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231016 Address after: Room 2024, Hebei Publishing Media Creative Center, No. 19 Yuanboyuan Street, Zhengding District, China (Hebei) Free Trade Pilot Zone, Shijiazhuang City, Hebei Province, 050899 Patentee after: Yuetenong biotechnology Hebei Co.,Ltd. Address before: 050000 1st floor, building 1, Hongchang Industrial Park, No. 238 Changjiang Avenue, high tech Zone, Shijiazhuang, Hebei Patentee before: Nongfuyu pharmaceutical Hebei Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231115 Address after: Room 2024, Hebei Publishing Media Creative Center, No. 19 Yuanboyuan Street, Zhengding District, China (Hebei) Free Trade Pilot Zone, Shijiazhuang City, Hebei Province, 050899 Patentee after: Yuetenong biotechnology Hebei Co.,Ltd. Address before: 050000 1st floor, building 1, Hongchang Industrial Park, No. 238 Changjiang Avenue, high tech Zone, Shijiazhuang, Hebei Patentee before: Nongfuyu pharmaceutical Hebei Co.,Ltd. |
|
TR01 | Transfer of patent right |